These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 3025043)

  • 1. Effect of aldose reductase inhibitor ONO 2235 on reduced sympathetic nervous system activity and peripheral nerve disorders in STZ-induced diabetic rats.
    Yoshida T; Nishioka H; Yoshioka K; Nakano K; Kondo M; Terashima H
    Diabetes; 1987 Jan; 36(1):6-13. PubMed ID: 3025043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of prostaglandin E1 analogue TFC 612 on diabetic neuropathy in streptozocin-induced diabetic rats. Comparison with aldose reductase inhibitor ONO 2235.
    Yasuda H; Sonobe M; Yamashita M; Terada M; Hatanaka I; Huitian Z; Shigeta Y
    Diabetes; 1989 Jul; 38(7):832-8. PubMed ID: 2525492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac sympathetic neuropathy and effects of aldose reductase inhibitor in streptozotocin-induced diabetic rats.
    Kurata C; Okayama K; Wakabayashi Y; Shouda S; Mikami T; Tawarahara K; Sugiyama T
    J Nucl Med; 1997 Nov; 38(11):1677-80. PubMed ID: 9374332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a new aldose reductase inhibitor, (E)-3-carboxymethyl-5-[(2E)-methyl-3-phenylpropenylidene]rhodanine (ONO-2235) on peripheral nerve disorders in streptozotocin-diabetic rats.
    Kikkawa R; Hatanaka I; Yasuda H; Kobayashi N; Shigeta Y; Terashima H; Morimura T; Tsuboshima M
    Diabetologia; 1983 Apr; 24(4):290-2. PubMed ID: 6407887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of aldose reductase inhibitor on microneurographically assessed peripheral sympathetic nerve activity in rats.
    Sato D; Kusunoki M; Shinzawa G; Feng Z; Nishina A; Nakamura T
    Auton Neurosci; 2015 Dec; 193():69-73. PubMed ID: 26272532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AL-1576, an aldose reductase inhibitor (ARI), did not prevent the decrease of norepinephrine turnover in diabetic rats.
    Yen TT; Fuller RW; Broderick CL; Hemrick-Luecke SK; Perry KW
    Res Commun Chem Pathol Pharmacol; 1988 Aug; 61(2):257-60. PubMed ID: 3141993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of peripheral nerve dysfunction by an aldose reductase inhibitor in streptozotocin-diabetic rats.
    Kikkawa R; Hatanaka I; Yasuda H; Kobayashi N; Shigeta Y
    Metabolism; 1984 Mar; 33(3):212-4. PubMed ID: 6420645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to improvement of diabetic neuropathy.
    Mizuno K; Kato N; Makino M; Suzuki T; Shindo M
    J Diabetes Complications; 1999; 13(3):141-50. PubMed ID: 10509874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of a fructose-rich diet and the aldose reductase inhibitor, ONO-2235, on the development of diabetic neuropathy in streptozotocin-treated rats.
    Hotta N; Kakuta H; Fukasawa H; Kimura M; Koh N; Iida M; Terashima H; Morimura T; Sakamoto N
    Diabetologia; 1985 Mar; 28(3):176-80. PubMed ID: 3922829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
    Shindo H; Tawata M; Aida K; Onaya T
    J Clin Endocrinol Metab; 1992 Feb; 74(2):393-8. PubMed ID: 1370506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of an aldose reductase inhibitor, ONO-2235, insulin and their combination on the altered responsiveness to the nerve stimulation and agonists of the isolated atria of diabetic rats.
    Hashimoto H; Satoh N; Takiguchi Y; Nakashima M
    J Pharmacol Exp Ther; 1990 May; 253(2):552-7. PubMed ID: 2159998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of the polyol pathway on norepinephrine transporter reduction in diabetic cardiac sympathetic nerves: implications for heterogeneous accumulation of MIBG.
    Kiyono Y; Kajiyama S; Fujiwara H; Kanegawa N; Saji H
    Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):438-42. PubMed ID: 15821963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A combination of the aldose reductase inhibitor, statil, and the prostaglandin E1 analogue, OP1206.alpha CD, completely improves sciatic motor nerve conduction velocity in streptozocin-induced chronically diabetic rats.
    Yasuda H; Sonobe M; Hisanaga T; Kawabata T; Maeda K; Kikkawa R; Shigeta Y
    Metabolism; 1992 Jul; 41(7):778-82. PubMed ID: 1320179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of a new aldose reductase inhibitor, (2S, 4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-ca rboxamid e (SNK-860), on the slowing of motor nerve conduction velocity and metabolic abnormalities in the peripheral nerve in acute streptozotocin-induced diabetic rats.
    Mizuno K; Kato N; Matsubara A; Nakano K; Kurono M
    Metabolism; 1992 Oct; 41(10):1081-6. PubMed ID: 1328819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of an aldose reductase inhibitor on altered sympathetic nerve responsiveness of isolated right atria in diabetic rats.
    Sato N; Hashimoto H; Takiguchi Y; Nakashima M
    Arzneimittelforschung; 1990 Jul; 40(7):763-6. PubMed ID: 2121149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of defects of axonal transport and nerve conduction velocity by oral administration of myo-inositol or an aldose reductase inhibitor in streptozotocin-diabetic rats.
    Mayer JH; Tomlinson DR
    Diabetologia; 1983 Nov; 25(5):433-8. PubMed ID: 6197336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of a new aldose reductase inhibitor, 8'-chloro-2',3'-dihydrospiro [pyrrolidine-3,6'(5'H)-pyrrolo[1,2,3-de] [1,4]benzoxazine]-2,5,5'- trione (ADN-138), on delayed motor nerve conduction velocity in streptozotocin-diabetic rats.
    Hirata Y; Fujimori S; Okada K
    Metabolism; 1988 Feb; 37(2):159-63. PubMed ID: 2828821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of aldose reductase inhibition on nerve conduction velocity and resistance to ischemic conduction block in experimental diabetes.
    Price DE; Airey CM; Alani SM; Wales JK
    Diabetes; 1988 Jul; 37(7):969-73. PubMed ID: 3133261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of aldose reductase inhibitor sorbinil on neuroaxonal dystrophy and levels of myo-inositol and sorbitol in sympathetic autonomic ganglia of streptozocin-induced diabetic rats.
    Schmidt RE; Plurad SB; Sherman WR; Williamson JR; Tilton RG
    Diabetes; 1989 May; 38(5):569-79. PubMed ID: 2497038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of the polyol pathway on norepinephrine transporter reduction in diabetic cardiac sympathetic nerves: implications for heterogeneous accumulation of MIBG.
    Kiyono Y; Kajiyama S; Fujiwara H; Kanegawa N; Saji H
    Eur J Nucl Med Mol Imaging; 2005 Aug; 32(8):993-7. PubMed ID: 16261676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.